ELIXIRGEN THERAPEUTICS
Live / Registered — Registered (as of 12 Dec 2023)
What this means for you
Registered since 12 Dec 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97976453
- Registration number
- 7244784
- Mark type
- Stylized text
- Filed
- 01 Dec 2021
- Published for opposition
- 28 Feb 2023
- Registered
- 12 Dec 2023
- Attorney of record
- Leonard D. Bowersox
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical drugs for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for medicinal purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for pharmaceutical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; preparations of organisms for medical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases
- Class 042 — Scientific and technological services: Research and development of vaccines and medicines; testing of pharmaceuticals; research in the field of pharmaceuticals
Owner
- Elixirgen Therapeutics, Inc., Baltimore, MD, US
- Elixirgen Therapeutics, Inc., Baltimore, MD, US
- Elixirgen Therapeutics, Inc., Baltimore, MD, US
Prosecution history
- 12 Dec 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 12 Dec 2023 — REGISTERED-PRINCIPAL REGISTER
- 07 Nov 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 06 Nov 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 13 Sept 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Sept 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Aug 2023 — USE AMENDMENT FILED
- 12 Sept 2023 — SOU EXTENSION 1 GRANTED
- 22 Aug 2023 — SOU EXTENSION 1 FILED
- 12 Sept 2023 — DIVISIONAL PROCESSING COMPLETE
- 22 Aug 2023 — DIVISIONAL REQUEST RECEIVED
- 28 Aug 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Aug 2023 — SOU TEAS EXTENSION RECEIVED
- 22 Aug 2023 — TEAS STATEMENT OF USE RECEIVED
- 22 Aug 2023 — TEAS REQUEST TO DIVIDE RECEIVED